Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance

Citius Pharmaceuticals IncTrade
Vanguard Tax Managed Fund FTSE Developed Markets ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.3. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRVEA
Market Cap
$20.01M
Sector
Health
52-Week High
$1.82$72.89
52-Week Low
$0.48$58.19
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Vanguard Tax Managed Fund FTSE Developed Markets ETF

VEA trades at $73.30, up 1.1% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with recent buying from Ferguson Shapiro and selling from Financial Advisory Corp. Technical indicators show overbought RSI conditions while maintaining strong momentum with ADX at 47.42. The fund offers international diversification with a low expense ratio of 0.03% and upcoming dividend payment.

VEA presents a compelling international diversification opportunity with strong technical momentum and cost efficiency. However, overbought conditions and mixed institutional sentiment suggest potential near-term volatility. The fund's focus on developed markets outside the US provides geographic diversification but remains exposed to global economic headwinds and currency fluctuations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Vanguard Tax Managed Fund FTSE Developed Markets ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VEA